临床与病理杂志2017，Vol.37Issue(10)：2038-2042,5.DOI:10.3978/j.issn.2095-6959.2017.10.003
非小细胞肺癌接受埃克替尼治疗进展后继发性T790M突变
Acquired T790M mutation in patients with non-small cell lung cancer who received icotinib progress
摘要
Abstract
Objective:To investigate the acquired T790M situation of the non-small cell lung cancer patients who received icotinib treatment progress.Methods:The ARMS method was used to detect the samples in 209 cases of EGFR 19del or L858R mutation non-small cell lung cancer.Results:There were 123 cases accompanied 19del and 86 cases accompanied L858R in 209 cases non-small cell lung cancer samples who received icotinib treatment progress,the acquired T790M mutation type patients was 45.93％ (96/209),icotinib treatment resistance after the acquired T790M mutation with 19 del/L858R group had statistical difference (P＜0.034).Conclusion:19 del patients who received treatment for icotinib are more likely to appear acquired T790M mutation than L858R patients from NSCLC,and we should attach importance to it.关键词
非小细胞肺癌/19del/L858R/T790MKey words
non-small cell lung cancer/19del/L858R/T790M引用本文复制引用
李剑英,许春伟,黄韵坚,黄章洲,庄武,陈华飞,魏建国..非小细胞肺癌接受埃克替尼治疗进展后继发性T790M突变[J].临床与病理杂志,2017,37(10):2038-2042,5.基金项目
国家临床重点专科建设项目(2013) （2013）
福建省科技厅引导性项目(2016Y0019,2015Y0011) （2016Y0019,2015Y0011）
绍兴市人民医院青年科研基金(2017A09) （2017A09）
嘉兴市科技局项目(2017BY18050).This work was supported by National Clinical Key Specialty Construction Program (2013) （2017BY18050）
Leading Project Foundation of Science Department of Fujian Province (2016Y0019,2015Y0011) （2016Y0019,2015Y0011）
Youth Research Foundation of Shaoxing People's Hospital of Zhejiang Province (2017A09),China. （2017A09）
